Today : 2025.06.03
D--95
|
14:30-14:50 | In-depth Look at the Intersection of the Cardio-Renal Metabolic System Merlin THOMAS (Monash University, Australia) |
![]() |
14:50-15:10 | The Expected Future Role of SGLT-2i in CKD from Nephrology Perspective Christoph WANNER (Division of Nephrology, University of Wuerzburg, Germany) |
![]() |
15:10-15:30 | Heart Failure Management - From HFrEF to HFpEF Kyung-Hee Kim (Division of Cardiology, Incheon Sejong General Hospital, Korea) |
Panel Discussion | ||
---|---|---|
|
![]() |
Eu Jeong KU (Chungbuk National University, Korea) |
![]() |
Soo Kyoung KIM (Gyeongsang National University, Korea) |
![]() |
14:30-14:50 | Innovation Story of Semaglutide: Basic Research into Clinical Benefit Thomas Bo JENSEN (Novo Nordisk, Denmark) |
![]() |
14:50-15:10 | Advanced Journey: Holistic Management with Injectable Semaglutide Nan-Hee KIM (Korea University, Korea) |
![]() |
15:10-15:30 | New Journey: Patient-centered Care with Oral Semaglutide Adie VILJOEN (East and North Hertfordshire NHS Trust, UK) |
Panel Discussion | ||
---|---|---|
|
![]() |
Mi Kyung KIM (Keimyung University, Korea) |
Ju Hee LEE (Chungnam National University, Korea) |
![]() |
14:30-14:50 | Expanded Usage of Zoledronic Acid Dughyun CHOI (Soonchunhyang University, Korea) |
![]() |
14:50-15:10 | The Cardiorenal Benefits of Dapagliflozin Miguel CAMAFORT-BABKOWSKI (University of Barcelona, Spain) |
![]() |
15:10-15:30 | Insights to Practical Use of Ambulatory Glucose Profile in Clinical Practice Iain CRANSTON (Portsmouth Hospitals NHS Trust, UK) |
Panel Discussion | ||
---|---|---|
|
![]() |
Soyeon YOO (Jeju National University, Korea) |
![]() |
Jin Ook CHUNG (Chonnam National University, Korea) |
![]() |
16:10-16:30 | Potential Benefits of DPP4 Inhibitors Beyond Glycemic Control: Calcific Aortic Valve Disease Jae-kwan SONG (Department of Cardiology, University of Ulsan, Korea) |
![]() |
16:30-16:50 | Optimal Combination Therapy for T2DM, DPP-4i + SGLT-2i Jun Sung MOON (Yeungnam University, Korea) |
![]() |
16:50-17:10 | NASH Related Clinical Drug Development: A Succinct Review of the NAFLD & NASH Landscape Marcus HOMPESCH (ProSciento, USA) |
Panel Discussion | ||
---|---|---|
|
![]() |
Kwang Joon KIM (Department of Geriatrics, Yonsei University , Korea) |
Hye Soon KIM (Keimyung University, Korea) |
![]() |
16:10-16:30 | Trends in Characteristics and Treatment of Type 2 Diabetes in Thailand Swangjit SURA-AMORNKUL (Navamindradhiraj University, Thailand) |
![]() |
16:30-16:50 | Trends in Characteristics and Treatment of Type 2 Diabetes in Philippines Jeremy F. ROBLES (Cebu Institute of Medicine, Philippine) |
![]() |
16:50-17:10 | Trends in Characteristics and Treatment of Type 2 Diabetes in Korea So Hun KIM (Inha University, Korea) |
![]() |
17:10-17:30 | Clinical Benefits of Gemigliptin for the Treatment of T2DM Jeong Hyun PARK (Inje University, Korea) |
![]() |
16:10-16:30 | DPP4i and Patient-tailored Treatment Juliana CHAN (The Chinese University of Hong Kong, Hong Kong SAR) |
![]() |
16:30-16:50 | TZD, Benefits on T2DM Patients beyond Glycemic Control Chih-Yuan WANG (National Taiwan University, Taiwan) |
![]() |
16:50-17:10 | What to Consider for Early Combination with DPP4-I & TZD Yongho LEE (Yonsei University, Korea) |
Panel Discussion | ||
---|---|---|
|
![]() |
Young Sang LYU (Chosun University, Korea) |
![]() |
Mihae SEO (Soonchunhyang University, Korea) |